Ryaltris nasal spray now available in US for patients aged 12 years and older

Key takeaways:

• Ryaltris combines olopatadine hydrochloride and mometasone furoate in a single nasal spray.
• The FDA approved the spray in January to treat ocular and nasal seasonal allergic rhinitis symptoms in patients aged 12 years and older.
• One in seven U.S. adults say their nasal allergy symptoms are poorly controlled or not controlled at all.

Olopatadine hydrochloride and mometasone furoate nasal spray is now available in the United States for the treatment of symptoms associated with seasonal allergic rhinitis in patients aged 12 years and older, according to a press release.

Olopatadine hydrochloride and mometasone furoate nasal spray (Ryaltris; Hikma Pharmaceuticals, Glenmark Specialty S.A.) is the only fixed-dose combination therapy that relieves both ocular and nasal seasonal allergic rhinitis symptoms, according to the press release. Symptom relief occurs within 15 minutes of the first dose. It is FDA-approved for treating seasonal allergic rhinitis symptoms in patients aged 12 years and older.

“Allergic rhinitis and allergic conjunctivitis are among the most common chronic diseases in the U.S. today, affecting 60 million Americans each year,” Leonard Bielory, MD, professor of allergy, immunology and ophthalmology at Hackensack Meridian School of Medicine, said in the press release.

However, approximately one in seven U.S. adults have reported that their nasal allergy symptoms are either poorly controlled or not controlled at all, and their ocular symptoms are as severe as their nasal symptoms, Bielory continued.

“By combining two of the most frequently prescribed medicines used to address both the nasal and ocular symptoms of seasonal allergic rhinitis into one easy-to-use nasal spray, Ryaltris provides an important new treatment option for patients suffering from this chronic condition affecting the nose and eyes,” Bielory said.

According to the press release, uncontrolled seasonal allergic rhinitis burdens patients and society alike as chronic complications may include asthma, sinusitis, hearing impairment and other allergy-related issues that can impact quality of life.

Treatment options such as this nasal spray could help treat seasonal allergic rhinitis because patients who do not experience adequate symptom relief may need escalated therapy including immunotherapy, biologics or surgery, the release continued, adding that these approaches come with higher costs and risks.

The recommended dosage is two sprays in each nostril twice a day. Each dose includes 665 µg of olopatadine hydrochloride, which is a histamine-1 receptor inhibitor, and 25 µg of mometasone furoate, which is a corticosteroid.

The spray is now available in major markets around the world.